Natalie Banniettis - JoVE Visualize

Showing results (31-40 of 34) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 34 results.

Pediatrics|June 13, 2023

Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.

Vaccines|January 28, 2026

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health SitesLaura L Hammitt, Ulrike K Buchwald, Jennifer McCauley, et al.

Vaccine|April 27, 2023

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.

Human Vaccines & Immunotherapeutics|March 18, 2024

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)Alvino Maestri, Su Eun Park, Fiona Fernandes, et al.

Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 34 results.

Pediatrics|June 13, 2023

Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.

Vaccines|January 28, 2026

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health SitesLaura L Hammitt, Ulrike K Buchwald, Jennifer McCauley, et al.

Vaccine|April 27, 2023

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, et al.

Human Vaccines & Immunotherapeutics|March 18, 2024

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)Alvino Maestri, Su Eun Park, Fiona Fernandes, et al.

Pageof 4